Locally Advanced Breast Cancer Clinical Trial
— TRIOOfficial title:
Evaluating the Use of Stereotactic Radiation Therapy Prior to Neoadjuvant Chemotherapy for High-risk Breast Carcinoma (a SIGNAL Series Clinical Trial): Three Fraction Radiation to Induce Immuno-Oncologic Response (TRIO Trial)
NCT number | NCT03978663 |
Other study ID # | 112626 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2, 2020 |
Est. completion date | August 2025 |
Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple negative and HER2-positive breast cancers) will receive neoadjuvant radiation to any portion of their tumour in three fractions in order to act as an immune primer. Radiation will be delivered to a portion of the tumour in three fractions. The patient will be positioned prone as per the SIGNAL 2.0 protocol. The patient will then go on to standard of care treatment (neoadjuvant chemotherapy and surgery) followed by whole-breast radiation as needed. Pathologic complete response will be the primary outcome. Immune markers will also be evaluated.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | August 2025 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Any biopsy-proven locally advanced breast cancer patient defined as Stages IIB-III (excluding inflammatory breast cancer). Stage IIA is eligible for triple negative and HER2-positive breast cancers 2. Invasive mammary carcinoma of any subtype excluding lobular, sarcomatous, or metaplastic subtypes, or with lobular features 3. Plan to be treated with neoadjuvant chemotherapy 4. Able to fit in/have MRI 5. 18 years of age or older 6. Able to tolerate core needle biopsies 7. Able to provide informed consent 8. No evidence of metastatic disease Exclusion Criteria: 1. Any serious medical comorbidities or other contraindications to radiotherapy, chemotherapy, or surgery 2. Prior treatment for current breast cancer 3. Previous radiation therapy to the same breast 4. Inflammatory breast carcinoma 5. Invasive lobular carcinoma or invasive mammary carcinoma with lobular, sarcomatous, or metaplastic subtypes, or with lobular features 6. Recurrent breast cancer 7. Bilateral breast cancer 8. Evidence of distant metastatic disease 9. Collagen vascular disease (particularly lupus, scleroderma, dermatomyositis, psoriatic arthritis) 10. Any other malignancy at any site (except non-melanomatous skin cancer) <5 years prior to study enrollment 11. Inability to lay prone with arms above the head for extended periods of time 12. Inability to fit in/have an MRI 13. Inability to tolerate core needle biopsies 14. Pregnant or lactating 15. Under 18 years of age 16. Inability or unwillingness to provide informed consent |
Country | Name | City | State |
---|---|---|---|
Canada | London Regional Cancer Program | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathologic complete response | Pathologic complete response rates after neoadjuvant radiotherapy and chemotherapy will be evaluated. | Measured at time of surgery, typically 6 months after enrollment in trial. | |
Secondary | Response rates in the primary post chemotherapy by imaging | Response rates in the primary post chemotherapy by MRI +/- PET scan compared to pre-neoadjuvant radiation imaging | Measured after neoadjuvant radiation and chemotherapy has been completed, prior to surgery, typically 6 months after enrollment in trial. | |
Secondary | Response rates in the axillary nodes post chemotherapy by imaging and pathology | Absence of any invasive breast cancer cells in any tissue at time of surgery | Measured after neoadjuvant radiation and chemotherapy has been completed, prior to surgery (imaging) and at time of surgery, typically 6 months after enrollment in trial. | |
Secondary | Immune priming | Immune priming as measured by amount of tumour infiltrating lymphocytes (CD8) into tumour specimen, as well as the expression of immune markers (PDL1, Fox3) and immune panel in blood (CD4, CD8, neutrophil, and macrophage counts). Angiogenesis will be examined using the CD31 or VEGF-a cell markers, proliferation will be examined using the Ki67 marker, hypoxia will be examined using the Carbonic Anhydrase 9 (CAH IX), or HIF1/HIF2 markers, apoptosis will be examined using the Caspase-3, or Tunnel markers, invasion will be analyzed using the vimentin, or SDF1-a markers. | Measured 14-20 days after the last dose of neoadjuvant radiation, prior to the start of neoadjuvant chemotherapy. | |
Secondary | Radiation toxicity | Toxicity to surrounding breast and skin tissue, defined by = grade 2 fibrosis. | Measured at study enrollment, at first surgical follow-up post-surgery, 6 months post surgery, and 1 year post surgery. | |
Secondary | Surgical wound healing and the overall complication rate. | Percentage of patients experiencing wound infection that requires wound to be opened and/or packed. | Measured at the first surgical follow-up post-surgery, 6 months post surgery, and 1 year post surgery. | |
Secondary | Local recurrence rates | Ipsilateral breast recurrence rate. | Disease status will be evaluated at routine patient follow-up appointments, including yearly mammography. Will be reported at year 3. | |
Secondary | Ability of imaging to predict patient response to radiotherapy. | Correlation between complete clinical response on imaging and pathological complete response. | Pre-treatment imaging to be done after study enrollment (baseline) and 14-20 days after the last dose of neoadjuvant radiation has been delivered. | |
Secondary | Ability of imaging markers to predict response to radiotherapy | Ability of FDG uptake, choline levels, perfusion, and ADC obtained from post-radiotherapy imaging to predict tissue response to high dose radiotherapy. | Pre-treatment imaging to be done after study enrollment (baseline measurements) and 14-20 days after the last dose of neoadjuvant radiation has been delivered. | |
Secondary | Ability to predict pathological response to treatment based on tumour genetics | Ability to predict pathological response to treatment based on microarray analysis of tumor gene expression. | Tissue samples for analysis will be taken 14-20 days after completion of neoadjuvant radiation, prior to the start of neoadjuvant chemotherapy and will be compared with tissue taken prior to the start of neoadjuvant radiation. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01048918 -
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer
|
||
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
Terminated |
NCT01837563 -
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
|
N/A | |
Active, not recruiting |
NCT04352777 -
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06064812 -
A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.
|
Phase 1 | |
Recruiting |
NCT05963997 -
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06080620 -
The Choice of Treatment Methods and Efficacy of LABC
|
N/A | |
Completed |
NCT05002868 -
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02595762 -
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
|
||
Active, not recruiting |
NCT02965950 -
The p53 Breast Cancer Trial
|
Phase 2 | |
Completed |
NCT01785992 -
A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.
|
Phase 2 | |
Completed |
NCT00764036 -
Study of Artesunate in Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03685331 -
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT05021900 -
Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT04088032 -
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
|
Early Phase 1 | |
Completed |
NCT00455273 -
Dynamic Breast MRI in Assessing Locally Advanced Breast Cancer
|
||
Terminated |
NCT04042051 -
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
|
Phase 1 | |
Recruiting |
NCT05582499 -
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05749016 -
Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer
|
Phase 2 |